CNS Neuroscience & Therapeutics
March 1, 2025
Zerui You, Xiaofeng Lan, Chengyu Wang et al.
1 citation
Despite the clinical benefits of ketamine in treating major depressive disorder (MDD), some patients exhibit drug resistance, and the intricate mechanisms underlying this await comprehensive explication. We used metabolomics to find biomarkers for ketamine efficacy and uncover its mechanisms of action. The study included 40 MDD patients treated with ketamine in the discovery cohort and 24...
CNS Neuroscience & Therapeutics
December 1, 2024
Xiaoyu Niu, Yuanyuan Zheng, Wang Wang et al.
7 citations
Esketamine (ESK), a noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors, modulates neurotransmitter signaling in the central nervous system. However, the specific mechanisms and therapeutic potential of ESK for intracerebral hemorrhage (ICH) remain unclear. This study aimed to investigate whether ESK promotes nerve repair and improves neurological outcomes in an experimental...
CNS Neuroscience & Therapeutics
April 1, 2024
Liang Zhou, Jingjing Duan
As a phencyclidine (PCP) analog, ketamine can generate rapid-onset and substantial anesthetic effects. Contrary to traditional anesthetics, ketamine is a dissociative anesthetic and can induce loss of consciousness in patients. Recently, the subanaesthetic dose of ketamine was found to produce rapid-onset and lasting antidepressant effects. However, how different concentrations of ketamine can...
CNS Neuroscience & Therapeutics
January 10, 2023
Jing Wang, Min Liang, Qing Shang et al.
23 citations
Abstract Aim Psilocin is an active metabolite form of psilocybin and exerts psychoactive effects. Recent studies suggest that psilocin may have regulatory effects on abuse drugs, but the mechanisms remain unclear. In this study, we want to explore the effects of psilocin on methamphetamine (METH)‐induced alterations of behavior in mice and its molecular mechanisms. Methods Acute METH...
CNS Neuroscience & Therapeutics
June 1, 2013
Ornella Corazza, Sulaf Assi, Fabrizio Schifano
147 citations
This article reviews the recreational use of ketamine ("Special K"; KET) and explores the recent diffusion of its new derivative methoxetamine ("Special M"; MXE). The literature search on the nonclinical/recreational use of KET and MXE was carried out in a range of medical databases. Considering the limitations of peer-reviewed information, data were integrated with a qualitative assessment of...
CNS Neuroscience & Therapeutics
April 12, 2013
Giacomo Salvadore, Jaskaran Singh
80 citations
Several recent studies have shown that a single intravenous subanesthetic dose of ketamine, a NMDA receptor antagonist, exerts rapid antidepressant effects in patients with treatment refractory mood disorders and reduces suicidal ideation. Those insights have fueled tremendous excitement in the efforts to elucidate the mechanism underlying ketamine's antidepressant properties in animal models...
CNS Neuroscience & Therapeutics
April 10, 2013
G. Mion, Thierry Villevieille
690 citations
For more than 50 years, ketamine has proven to be a safe anesthetic drug with potent analgesic properties. The active enantiomer is S(+)-ketamine. Ketamine is mostly metabolized in norketamine, an active metabolite. During "dissociative anesthesia", sensory inputs may reach cortical receiving areas, but fail to be perceived in some association areas. Ketamine also enhances the descending...
CNS Neuroscience & Therapeutics
April 2, 2011
Thilo Deckersbach, Britta K. Hölzel, Lori Eisner et al.
130 citations
INTRODUCTION: Bipolar disorder is characterized by recurrent episodes of depression and/or mania along with interepisodic mood symptoms that interfere with psychosocial functioning. Despite periods of symptomatic recovery, many individuals with bipolar disorder continue to experience substantial residual mood symptoms that often lead to the recurrence of mood episodes. AIMS: This study explored...
CNS Neuroscience & Therapeutics
November 11, 2008
Torsten Passie, John H. Halpern, Dirk O. Stichtenoth et al.
459 citations
Lysergic acid diethylamide (LSD) was synthesized in 1938 and its psychoactive effects discovered in 1943. It was used during the 1950s and 1960s as an experimental drug in psychiatric research for producing so‐called “experimental psychosis” by altering neurotransmitter system and in psychotherapeutic procedures (“psycholytic” and “psychedelic” therapy). From the mid 1960s, it became an illegal...